In an animal reproduction study, intravenous administration of cetuximab once weekly to pregnant cynomolgus monkeys during the period of organogenesis resulted in an increased incidence of embryolethality and abortion. In MONARCH 3, the median time to onset of the first diarrhea event was 8 days, and the median duration of diarrhea for Grades 2 and 3 were 11 and 8 days, respectively. The data include positive results from the Phase 3 monarchE study of Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for the treatment of high risk HR+, HER2- early breast cancer. Episodes of diarrhea have been associated with dehydration and infection. TYVYT monotherapy met the primary endpoint in the ORIENT-2 study as second-line therapy in patients with advanced or metastatic esophageal squamous cell carcinoma as well. brief introduction: Albert has 15 years of experience in the financial field and has worked in the Audit and Trading Consulting department of PWC, providing IPO audits, annual audits, transaction due diligence, post management, transaction integration and other related financial advisory services. ILD, which was fatal in one case, occurred in <0.5% of 1570 patients receiving ERBITUX in clinical trials. IMPORTANT SAFETY INFORMATION FOR RETEVMO™ (selpercatinib). Permanently discontinue CYRAMZA in patients who develop PRES. All rights reserved. Based on safety data from REACH-2, in patients with Child-Pugh A liver cirrhosis, the pooled incidence of hepatic encephalopathy and hepatorenal syndrome was higher for patients who received CYRAMZA (6%) compared to patients who received placebo (0%). Determine creatinine clearance before each dose and periodically monitor renal function during treatment with ALIMTA. Permanently discontinue Retevmo for recurrent hypersensitivity. Concomitant use of strong and moderate CYP3A inhibitors increase selpercatinib plasma concentrations which may increase the risk of Retevmo adverse reactions including QTc interval prolongation. To learn more about Lilly's commitment to people with cancer, please visit www.LillyOncology.com. DUBLIN--(BUSINESS WIRE)--The "Aurora-A Kinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to … Preclinically, Verzenio dosed daily without interruption resulted in reduction of tumor size. Withhold ALIMTA for acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, or fever pending diagnostic evaluation. Red blood cell transfusions were given to 3.2% of CYRAMZA-treated patients versus 0 patients who received placebo. Serious, including fatal, hemorrhagic events can occur with Retevmo. Initiate or adjust anti-hypertensive therapy as appropriate. The most common adverse reactions leading to treatment discontinuation of CYRAMZA were proteinuria (8.6%) and hyperbilirubinemia (6%). The most common adverse reactions in ERBITUX clinical trials (incidence ≥25%) include cutaneous adverse reactions (including rash, pruritus, and nail changes), headache, diarrhea, and infection. Do not initiate Retevmo in patients with uncontrolled hypertension. Monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism and treat as medically appropriate. Additional Verzenio data to be presented include a final overall survival analysis of Verzenio monotherapy in patients with HR+, HER2- advanced breast cancer in the nextMONARCH trial. In Studies JMDB and JMCH, among patients who received vitamin supplementation, incidence of Grade 3-4 neutropenia was 15% and 23%, the incidence of Grade 3-4 anemia was 6% and 4%, and incidence of Grade 3-4 thrombocytopenia was 4% and 5%, respectively. Acneiform rash usually developed within the first 2 weeks of therapy; the rash lasted more than 28 days after stopping ERBITUX in most patients. Radiation recall can occur with ALIMTA in patients who have received radiation weeks to years previously. Together, the studies presented at ESMO demonstrate Lilly's commitment to researching and developing new treatments for people around the world who are living with cancer. If pneumonitis is confirmed, permanently discontinue ALIMTA. The safety of resumption of CYRAMZA after resolution of wound healing complications has not been established. A list of the data presentations along with the viewing details are highlighted below. © Lilly USA, LLC 2020. Please see full U.S. Prescribing Information for CYRAMZA. Monitor the QT interval more frequently when Retevmo is concomitantly administered with strong and moderate CYP3A inhibitors or drugs known to prolong QTc interval. Permanently discontinue CYRAMZA in patients who experience an ATE. IRR, including severe and life-threatening IRR, occurred in CYRAMZA clinical trials. The most common adverse reactions (all Grades) observed in patients treated with CYRAMZA with docetaxel at a rate of ≥5% and ≥2% higher than placebo with docetaxel were neutropenia (55% vs 46%), fatigue/asthenia (55% vs 50%), stomatitis/mucosal inflammation (37% vs 19%), epistaxis (19% vs 7%), febrile neutropenia (16% vs 10%), peripheral edema (16% vs 9%), thrombocytopenia (13% vs 5%), lacrimation increased (13% vs 5%), and hypertension (11% vs 5%). TYVYT is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1/ PD-Ligand 1 (PD-L1) pathway and reactivates T-cells to kill cancer cells. Because ERBITUX provides approximately 22% higher exposure relative to the cetuximab product used in EXTREME, the data provided above may underestimate the incidence and severity of adverse reactions anticipated with ERBITUX for this indication. Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis. Retevmo™ Data Highlights In May 2020, Lilly's first-in-class oral precision medicine Retevmo™ (selpercatinib) received Accelerated Approval from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC), in adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, and in adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). With severe hepatic impairment (Child-Pugh Class C), reduce the Verzenio dosing frequency to once daily. The most common adverse reactions (all grades; incidence ≥25%) seen in patients with carcinomas of the head and neck receiving ERBITUX in combination with radiation therapy (n=208) versus radiation alone (n=212) (BONNER) were acneiform rash (87% vs 10%), radiation dermatitis (86% vs 90%), weight loss (84% vs 72%), asthenia (56% vs 49%), nausea (49% vs 37%), increased alanine transaminase (43% vs 21%), increased aspartate transaminase (38% vs 24%), increased alkaline phosphatase (33% vs 24%), fever (29% vs 13%), emesis (29% vs 23%), pharyngitis (26% vs 19%) and dehydration (25% vs 19%). For assessment of potential hepatotoxicity, monitor liver function tests (LFTs) prior to the start of Verzenio therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Do not administer CYRAMZA for at least 2 weeks following a major surgical procedure and until adequate wound healing. If coadministration cannot be avoided, follow recommendations for CYP2C8 and CYP3A substrates provided in their approved product labeling. The Athenex team continues to fuel the rapid expansion of this clinical pipeline now comprised of nine total IND’s. Diarrhea incidence was greatest during the first month of Verzenio dosing. Serious and sometimes fatal, bullous, blistering, and exfoliative skin toxicity, including cases suggestive of Stevens-Johnson Syndrome/toxic epidermal necrolysis, can occur with ALIMTA. There are no available data for ERBITUX exposure in pregnant women. In patients with recommended starting doses of 200 mg twice daily or 150 mg twice daily, reduce the Verzenio dose to 100 mg twice daily with concomitant use of  strong CYP3A inhibitors other than ketoconazole. Correct hypokalemia, hypomagnesemia and hypocalcemia prior to initiating Retevmo and during treatment. Indications and Usage for ERBITUX (cetuximab) injection. The deal for Eli Lilly to acquire Loxo Oncology is valued at about $8 billion. The most common grade 3 and 4 adverse reactions for a cetuximab product in combination with CT (≥10%) versus CT alone was infection (11% vs 8%). Verify pregnancy status in females of reproductive potential prior to initiating ERBITUX. ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline … Permanently discontinue CYRAMZA for urine protein levels greater than 3 grams over 24 hours or in the setting of nephrotic syndrome. Venous thromboembolic events included deep vein thrombosis, pulmonary embolism, pelvic venous thrombosis, cerebral venous sinus thrombosis, subclavian and axillary vein thrombosis, and inferior vena cava thrombosis. Retevmo is indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), and the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). Advise females of reproductive potential to use effective contraception during treatment with ERBITUX and for 2 months after the last dose of ERBITUX. However, the tolerability of the recommended dose is supported by safety data from additional studies of ERBITUX. Avoid concomitant use of the strong CYP3A inhibitor ketoconazole. High-impact upcoming events comprise topline Phase II and Phase III trial results, an expected PDUFA date for supplemental NDA, an estimated supplemental CHMP opinion, and an estimated supplemental European approval. The most common adverse reactions (all Grades) observed in patients treated with CYRAMZA with erlotinib at a rate of ≥ 5% and ≥2% higher than placebo with erlotinib were infections (81% vs 76%), diarrhea (70% vs 71%), hypertension (45% vs 12%), stomatitis (42% vs 36%), alopecia (34% vs 20%), epistaxis (34% vs 12%), proteinuria (34% vs 8%), peripheral edema (23% vs 4%), headache (15% vs 7%), gastrointestinal hemorrhage (10% vs 3%), gingival bleeding (9% vs 1%), and pulmonary hemorrhage (7% vs 2%). The most common grade 3 and 4 adverse reactions (≥10%) included: neutropenia (31% vs 24%), acne-like rash (18% vs <1%), and diarrhea (16% vs 10%). Copyright © 2021 Eli Lilly and Company. The Netherlands, Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies, today announced a research collaboration and exclusive license agreement that … If concomitant use of a strong or moderate CYP3A inhibitor cannot be avoided, reduce the Retevmo dosage as recommended and monitor the QT interval with ECGs more frequently. Avoid concomitant use of strong and moderate CYP3A inhibitors with Retevmo. Premedicate prior to each CYRAMZA infusion. Advise females of reproductive potential to use effective contraception during treatment with ALIMTA and for 6 months after the final dose. Because of the potential risk for serious adverse reactions in breastfed children from ramucirumab, advise women not to breastfeed during treatment with CYRAMZA and for 2 months after the last dose. ACROFAN=Businesswire | webmaster@businesswire.com | SNS. Eli Lilly’s acquisition of Loxo has added the FDA approved asset VITRAKVI and the early- and mid-stage oncology pipeline assets LOXO-305, LOXO-195, and LOXO-292. Based on animal data and its mechanism of action, ERBITUX can cause fetal harm when administered to a pregnant woman. Reduce the dose when administering Retevmo to patients with severe hepatic impairment (total bilirubin greater than 3 to 10 times upper limit of normal [ULN] and any AST). The most common adverse reactions (all grades; incidence ≥25%) seen in patients with carcinomas of the head and neck receiving a cetuximab product in combination with platinum-based therapy and fluorouracil (CT) (n=219) versus CT alone (n=215) (EXTREME) were acneiform rash (70% vs 2%), nausea (54% vs 47%), infection (44% vs 27%), rash (28% vs 2%), diarrhea (26% vs 16%) and anorexia (25% vs 14%). Adverse reactions with fatal outcome were reported in 4% of patients in the ERBITUX combination arm and 3% in the control arm. The most frequently reported ≥5% Grade 3 or 4 adverse reactions that occurred in the Verzenio arm vs the placebo arm of MONARCH 3 were neutropenia (22% vs 2%), diarrhea (9% vs 1%), leukopenia (8% vs <1%), ALT increased (7% vs 2%), and anemia (6% vs 1%). Abstract LBA5_PR: Abemaciclib in high risk early breast cancer (Stephen R. Johnston) Accepted for Presidential Symposium II September 20 at 19:51-20:03 CEST, Abstract 273O: nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer (Erika P. Hamilton) Accepted as Oral Presentation September 19 at 17:28-17:40 CEST; Session: Breast Cancer, Metastatic 1, Abstract 174P: Genomic testing, biomarkers and treatment patterns in early breast cancer (Michael Method) Accepted as ePoster Available on-demand on September 17 at 09:00 CEST, Abstract 181P: The use of Ki67 testing and scoring in HR+, HER2- early breast cancer (Jacqueline Brown) Accepted as ePoster Available on-demand on September 17 at 09:00 CEST, Abstract 240P: A multinational real-world study on HR+, HER2- early stage breast cancer patients' disease awareness, satisfaction, and involvement in treatment decisions (Alex Rider) Accepted as ePoster Available on-demand on September 17 at 09:00 CEST, Abstract 239P: Impact of clinical characteristics, patients' perception of treatment goals and endocrine therapy history on HRQOL in HR+, HER2- early stage breast cancer patients (Rhys Williams) Accepted as ePoster Available on-demand on September 17 at 09:00 CEST, Abstract 1291P: Hypersensitivity reactions (HR) to selpercatinib in RET fusion+ non-small cell lung cancer (NSCLC) patients (pts) following immune checkpoint inhibition (CPI) (Caroline E. McCoach) Accepted as ePoster Available on-demand on September 17 at 09:00 CEST, Abstract 1290P: Efficacy and safety with selpercatinib by last prior systemic therapy received in patients (Pts) with RET fusion + non-small cell lung cancer (NSCLC) (Oliver Gautschi) Accepted as ePoster Available on-demand on September 17 at 09:00 CEST, Abstract 1292P: Exploratory patient-reported outcomes (PROs) among patients with RET-fusion non-small cell lung cancer (NSCLC) in LIBRETTO-001: A phase I/II trial of selpercatinib (Anna R. Minchom) Accepted as ePoster Available on-demand on September 17 at 09:00 CEST, Abstract 1922P: Exploratory patient-reported outcomes among patients with RET-mutant medullary thyroid cancer in LIBRETTO-001: A phase I/II trial of selpercatinib (LOXO-292) (Lori J. Wirth) Accepted as ePoster Available on-demand on September 17 at 09:00 CEST, Abstract 1413TiP: LIBRETTO-431: Selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC) (Herbert H. Loong) Accepted as ePoster (trial in progress; no data will be presented) Available on-demand on September 17 at 09:00 CEST, Abstract 1927TiP: LIBRETTO-531: Selpercatinib in patients with treatment (Tx)-naïve RET-mutant medullary thyroid cancer (MTC) (Jorge Hernando) Accepted as ePoster (trial in progress; no data will be presented) Available on-demand on September 17 at 09:00 CEST, Abstract 1294P: RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type (Kazuhiko Nakagawa) Accepted as ePoster Available on-demand on September 17 at 09:00 CEST, Abstract 1357P: Outcomes of treated patients with EGFR-mutated advanced or metastatic non-small cell lung cancer harboring exon 19 deletions or L858R substitution (Exon 21) mutations: A systematic literature review (Katherine B. Winfree) Accepted as ePoster Available on-demand on September 17 at 09:00 CEST, Abstract 1298P: RELAY, ramucirumab plus erlotinib (RAM+ERL) versus placebo plus erlotinib (P+ERL) in untreated EGFR mutated metastatic non-small cell lung cancer (NSCLC): Exposure-response relationship (Kazuhiko Nakagawa) Accepted as ePoster Available on-demand on September 17 at 09:00 CEST, Abstract 1015TiP: Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: An expansion cohort of the phase III REACH-2 study (Richard S. Finn) Accepted as ePoster (trial in progress; no data will be presented) Available on-demand on September 17 at 09:00 CEST, Abstract 991P: Sintilimab plus IBI305 as first-line treatment for advanced hepatocellular carcinoma (Fan Jia) Accepted as ePoster Available on-demand on September 17 at 09:00 CEST, Abstract 1498TiP: A multi-center, randomized, open-label, phase III study of sintilimab + ramucirumab as 1st-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-106) (Ruihua Xu) Accepted as ePoster (trial in progress; no data will be presented) Available on-demand on September 17 at 09:00 CEST, Abstract 1313P: Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC (Makoto Nishio) Accepted as ePoster Available on-demand on September 17 at 09:00 CEST, Abstract 455P: A meta-analysis of efficacy and safety of cetuximab with biweekly vs. weekly dosing (Aparna Parikh) Accepted as ePoster Available on-demand on September 17 at 09:00 CEST. CYRAMZA inhibited angiogenesis in an in vivo animal model. Adverse reactions occurring at a 10% or higher incidence in patients receiving CYRAMZA with erlotinib and with a 10% or greater difference between patients aged 65 or older compared to patients aged less than 65 years were: diarrhea (75% versus 65%), hypertension (50% versus 40%), increased ALT (49% versus 35%), increased AST (49% versus 33%), stomatitis (46% versus 36%), decreased appetite (32% versus 19%), dysgeusia (23% versus 12%), and weight loss (19% versus 6%). Hepatocellular Carcinoma CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha-fetoprotein (AFP) of ≥400 ng/mL and have been treated with sorafenib. The most common serious adverse reactions with CYRAMZA were anemia (3.8%) and intestinal obstruction (2.1%). If a patient taking Verzenio discontinues a strong CYP3A inhibitor, increase the Verzenio dose (after 3 to 5 half-lives of the inhibitor) to the dose that was used before starting the inhibitor. The median time to first onset for increased AST was 4.1 weeks (range: 5 days to 2 years) and increased ALT was 4.1 weeks (range: 6 days to 1.5 years). In 2137 patients with various cancers treated with CYRAMZA in which premedication was recommended or required, the incidence of all Grade IRR ranged from <1- 9%. Pipeline Clinical Trials Technology. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with Verzenio and other CDK4/6 inhibitors. About Verzenio® (abemaciclib) Verzenio (abemaciclib) is an inhibitor of cyclin-dependent kinases (CDK)4 & 6, which are activated by binding to D-cyclins. Withhold, reduce dose or permanently discontinue Retevmo based on the severity. In EXTREME, where a cetuximab product was administered in combination with platinum-based therapy, the addition cetuximab to cisplatin and fluorouracil resulted in an increased incidence of hypomagnesemia of any grade (14%) and of Grade 3 or 4 hypomagnesemia (7%). The most common grade 3 and 4 adverse reactions (≥10%) included: fatigue (31% vs 29%), pain-other (18% vs 10%), rash/desquamation (16% vs 1%), dyspnea (16% vs 13%), other-gastrointestinal (12% vs 5%), and infection without neutropenia (11% vs 5%). These include several studies investigating CYRAMZA in combination with other anti-cancer therapies for the treatment of multiple tumor types. Exposure to ALIMTA is increased in patients with mild to moderate renal impairment who take concomitant ibuprofen, increasing the risks of adverse reactions of ALIMTA. If concomitant ibuprofen use cannot be avoided, monitor patients more frequently for ALIMTA adverse reactions, including myelosuppression, renal, and gastrointestinal toxicity. Symptoms of PRES include seizure, headache, nausea/vomiting, blindness, or altered consciousness, with or without associated hypertension. About Eli Lilly and Company External Innovation. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with Retevmo and for at least 1 week after the final dose. "We're thrilled to share the statistically significant and clinically meaningful results from monarchE, a Phase 3 study which demonstrated the impact of Verzenio, in combination with adjuvant endocrine therapy, to reduce the risk of cancer returning and potentially change the treatment landscape in high risk early breast cancer," said Maura Dickler, M.D., vice president, late phase development, Lilly Oncology. Based on findings from animal studies and its mechanism of action, ALIMTA can cause fetal harm when administered to a pregnant woman. Adverse reactions resulting in discontinuation of any component of the CYRAMZA with paclitaxel combination in ≥2% of patients in RAINBOW were neutropenia (4%) and thrombocytopenia (3%).